Freedom of Information Request: 0378
University Hospitals Birmingham NHS Foundation Trust (UHB) completed a merger by acquisition of Heart of England NHS Foundation Trust (HEFT) on 1st April 2018. UHB includes Birmingham Heartlands Hospital, the Queen Elizabeth Hospital Birmingham, Solihull Hospital and Community Services, Good Hope Hospital in Sutton Coldfield and Birmingham Chest Clinic.
Due to historical differences in data collection/reporting across UHB and the former Heart of England NHS Foundation Trust some responses have been provided by hospital site.
Queen Elizabeth Hospital
Please find below a request for information regarding the use of medicines to treat patients with psoriasis at your Trust.
Questions
1. How many patients with plaque psoriasis in your Trust are currently being treated with unlicensed Fumaderm?
0
2. How many patients with plaque psoriasis in your trust are currently being treated with Skilarence?
13
3. Is the Trust starting patients with plaque psoriasis on Skilarence?
Yes
4. If yes to Q3, how many patients in the last 6 months?
6
5. Is the Trust starting patients with psoriasis on unlicensed Fumaderm?
No
6. If yes to Q4, how many patients in the last 6 months?
Not Applicable
5. Does the Trust intend to review all patients with plaque psoriasis taking unlicensed Fumaderm in order to move them to a licensed formulation where appropriate?
Already reviewed and completed.
6. Please describe the process in place to achieve Q5 and the anticipated completion date.
See above
7. If the Trust does not intend to initiate Skilarence or review all patients with plaque psoriasis taking unlicensed Fumaderm, please provide an explanation why the Trust intends to continue with its current practice.
Not Applicable.
Heartlands, Good Hope and Solihull Hospital
Please find below a request for information regarding the use of medicines to treat patients with psoriasis at your Trust.
Questions
1. How many patients with plaque psoriasis in your Trust are currently being treated with unlicensed Fumaderm?
0
2. How many patients with plaque psoriasis in your trust are currently being treated with Skilarence?
3 patients
3. Is the Trust starting patients with plaque psoriasis on Skilarence?
Yes
4. If yes to Q3, how many patients in the last 6 months?
3 Patients are currently on Skilarence
5. Is the Trust starting patients with psoriasis on unlicensed Fumaderm?
No
6. If yes to Q4, how many patients in the last 6 months?
Not applicable
7. Does the Trust intend to review all patients with plaque psoriasis taking unlicensed Fumaderm in order to move them to a licensed formulation where appropriate?
Not applicable as all patients are on licensed formulation
8. Please describe the process in place to achieve Q5 and the anticipated completion date.
Not applicable
9. If the Trust does not intend to initiate Skilarence or review all patients with plaque psoriasis taking unlicensed Fumaderm, please provide an explanation why the Trust intends to continue with its current practice.
Not applicable
